| Literature DB >> 18570670 |
Abstract
Despite the marked advances in research on insulin resistance (IR) in humans and animal models of insulin resistance, the mechanisms underlying high salt-induced insulin resistance remain unclear. Insulin resistance is a multifactorial disease with both genetic and environmental factors (such as high salt) involved in its pathogenesis. High salt triggers insulin resistance in genetically susceptible patients and animal models of insulin resistance. One of the mechanisms by which high salt might precipitate insulin resistance is through its ability to enhance an oxidative stress-induced inflammatory response that disrupts the insulin signaling pathway. The aim of this hypothesis is to discuss two complementary approaches to find out how high salt might interact with genetic defects along the insulin signaling and inflammatory pathways to predispose to insulin resistance in a genetically susceptible model of insulin resistance. The first approach will consist of examining variations in genes involved in the insulin signaling pathway in the Dahl S rat (an animal model of insulin resistance and salt-sensitivity) and the Dahl R rat (an animal model of insulin sensitivity and salt-resistance), and the putative cellular mechanisms responsible for the development of insulin resistance. The second approach will consist of studying the over-expressed genes along the inflammatory pathway whose respective activation might be predictive of high salt-induced insulin resistance in Dahl S rats. Variations in genes encoding the insulin receptor substrates -1 and/or -2 (IRS-1, -2) and/or genes encoding the glucose transporter (GLUTs) proteins have been found in patients with insulin resistance. To better understand the combined contribution of excessive salt and genetic defects to the etiology of the disease, it is essential to investigate the following question:Question 1: Do variations in genes encoding the IRS -1 and -2 and/or genes encoding the GLUTs proteins predict high salt-induced insulin resistance in Dahl S rats?A significant amount of evidence suggested that salt-induced oxidative stress might predict an inflammatory response that upregulates mediators of inflammation such as the nuclear factor- kappa B (NF-kappa B), the tumor necrosis factor-alpha (TNF-alpha) and the c-Jun Terminal Kinase (JNK). These inflammatory mediators disrupt the insulin signaling pathway and predispose to insulin resistance. Therefore, the following question will be thoroughly investigated:Question 2: Do variations in genes encoding the NF-kappa B, the TNF-alpha and the JNK, independently or in synergy, predict an enhanced inflammatory response and subsequent insulin resistance in Dahl S rats in excessive salt environment?Finally, to better understand the combined role of these variations on glucose metabolism, the following question will be addressed:Question 3: What are the functional consequences of gene variations on the rate of glucose delivery, the rate of glucose transport and the rate of glucose phosphorylation in Dahl S rats?The general hypothesis is that "high-salt diet in combination with defects in candidate genes along the insulin signaling and inflammatory pathways predicts susceptibility to high salt-induced insulin resistance in Dahl S rats".Entities:
Mesh:
Substances:
Year: 2008 PMID: 18570670 PMCID: PMC2459151 DOI: 10.1186/1475-2840-7-19
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Figure 1Mechanism of High Salt-Induced Insulin Resistance in Dahl S rats. Our proposed model of high salt-induced insulin resistance in Dahl S rats depends on the combined contributions of high salt and genetic defects along the insulin signaling and inflammatory pathways, which in turn predispose Dahl S rats to an augmented inflammatory response and overt insulin resistance.
Figure 2Illustration of the Insulin Pathway and its Potential Contribution to High Salt-Induced Insulin Resistance in Dahl S rats. When insulin activates the insulin receptor in vivo, tyrosine phosphorylation of the IRS-1 and IRS-2 activates phosphoinositide 3 kinase (PI3K) enzyme, whose activation in turn stimulates the serine phosphorylation of Akt (Protein kinase B) [108]. The latter enzyme (PKB) stimulates glucose transport in muscle and adipose tissue through the stimulated translocation of glucose transporter GLUT4 isoform [109]. PKB also stimulates glycogen synthesis in the liver and muscle, and stimulates lipogenesis in adipose tissue. Existence of variants in genes encoding IRS-1 and/or-2 and glucose transporter proteins might impair insulin signaling by suppressing the IRS-1 and/or -2 mRNA levels, protein levels and activity or enhancing serine phosphorylation of IRS-1 and -2 resulting in high salt-induced insulin resistance in Dahl S rats.
Chromosomal location, genomic and protein sizes of IRS-1 and IRS-2 in rats
| Insulin receptor substrate 1 (IRS-1) | chr9:81585251–81638071 | 5365 bases | 3708 bases | Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. |
| Insulin receptor substrate 2 (IRS-2) | chr16:18878139–18889441 | 24234 bases | 3963 bases | Ubiquitin-mediated degradation of IRS1 and IRS2 promotes insulin resistance. IRS2 dysfunction is critical in the development of type 2 diabetes. Insulin was not able to suppress gluconeogenic gene expression in primary hepatocytes lacking IRS-2, but when IRS-2 signaling was reconstituted, these cells recovered this response to insulin. |
Summary of IRS-1 and -2 genes demonstrating their chromosomal location, respective genomic and coding sequence sizes, and known effects of their dysregulation.
Previously identified variant (s) in IRS-1 gene in rats
| Sprague Dawley | Non-synonymous | 1160 | ENSRNOSNP2552231 | T/C |
Table showing previously reported IRS-1 variant in Sprague Dawley rats compared to Brown Norway rats. The IRS-1 non-synonymous variant caused an amino acid change from Cysteine to Tyrosine. Functional assessment of such variant is yet to be determined [133].
Figure 3Contribution of IRS-1 and/or-2 variants to Insulin Resistance. Mechanisms by which IRS-1 and/or -2 variants contribute to insulin resistance include: 1) altering IRS-1 and/or-2 expression and function, 2) reduced IRS-1 and/or -2 binding to the insulin receptor, 3) a defect in binding of IRS-1 and/or -2 variant (s) to the p85 regulatory subunit of the PI3-kinase and a decrease in PI3-kinase activity. The latter leads to either a decreased GLUT4 translocation to the plasma membrane, further reducing glucose transport and glycogen synthesis, or a significant IRS-1 and/or -2 -induced decrease in phosphorylation of glycogen synthase kinase-3 (GSK-3), an enzyme that is important in glycogen synthesis, thus causing reduced glycogen synthesis, 4) reduced IRS-1 content that is not compensated by a constitutive increase in the IRS-2 protein content. This result in a reduced insulin-stimulated PI3-kinase activity and a significant decrease in Akt phosphorylation and activity.
Figure 4Structural Determinants of Insulin Receptor Substrates. IRS-1 and -2 are considerably similar in their general architecture [23,24,38]. They are composed of an NH2-terminal, pleckstrin homology (PH) domain that binds to membrane phospholipids, a phosphotyrosine binding (PTB) domain located just upstream the PH domain and is involved in the recognition of the asparagines-proline-glutamic acid-phosphotyrosine (NPEpY) sequence located in the juxtamembrane region of the insulin receptor β subunit, phosphoserine binding domain (PSB), and a less conserved COOH-terminal portion with multiple tyrosine phosphorylation motifs that can bind to specific SH2 domain-containing proteins.
Figure 5Serine phosphorylation in Dahl S rats precipitates insulin resistance. Dahl S rats are postulated in the current proposal to have increased serine phosphorylation of insulin receptor substrate-1 and/or 2 (IRS-1 and/or-2) on critical sites such as Ser 312, 616, 307, and 323. This in turn reduces their ability to bind and activate either the insulin receptor or the phosphoinositol 3-kinase, resulting in reduced insulin-stimulated glucose transport activity and other events downstream of PI3K.
Chromosomal location, tissue distribution and transcript information of genes encoding glucose transporters
| Slc2a1 | facilitated glucose transporter member 1 (Glucose transporter type 1) (GLUT-1) | chr5:139690804–139719021 | All tissues (abundant in brain and erythrocytes) | Basal uptake | |
| Slc2a2 | solute carrier family 2, facilitated glucose transporter member 2 (Glucose transporter type 2) (GLUT-2) | chr2:116036427–116065870 | Liver, pancreatic islet cells, retina | Glucose sensing | |
| Slc2a3 | solute carrier family 2, facilitated glucose transporter member 3 (Glucose transporter type 3) (GLUT-3) | chr4:159210019–159221248 | All tissues specially the brain | Supplements GLUT1 in tissues with high energy demand | |
| Slc2a4 | solute carrier family 2, facilitated glucose transporter member 4 (Glucose transporter type 4) (GLUT-4). | chr10:56,786,705–56,792,209. | Muscle, fat, heart | Insulin responsive | |
| Slc2a8 | solute carrier family 2, facilitated glucose transporter member 8 (Glucose transporter type 8) (GLUT-8) | chr3:11962578–11972099 | hippocampal neurons, testis, whole brain | ||
| Naglt1 | Sodium dependant glucose transporter 1 | chr20:44,147,331–44,176,308. | In all cells | ||
| Slc37a4 | solute carrier family 37 (glucose-6-phosphate transporter), member 4 | chr 8: 47,363,896–47,369,981. | Liver, Adipocytes |
Previously reported variant (s) in genes encoding glucose transporter proteins
| Sprague Dawley | Synonymous | 383 | ENSRNOSNP1925604 | C/T | |
| Sprague Dawley | Non-synonymous | 475 | ENSRNOSNP1165255 | A/G | |
| Sprague Dawley | Non-synonymous | 512 | ENSRNOSNP1165256 | G/A | |
| Sprague Dawley | Synonymous | 520 | ENSRNOSNP1165257 | T/A | |
| Sprague Dawley | Non-synonymous | 50 | rs8172435 | G/C | |
| Sprague Dawley | Synonymous | 147 | rs8160316 | A/C | |
| Sprague Dawley | Non-synonymous | 442 | rs8172437 | A/G | |
| Sprague Dawley | Non-synonymous | 465 | rs8172438 | C/G | |
| Sprague Dawley | Non-synonymous | 166 | ENSRNOSNP1513056 | C/A |
Previously reported variants in the glucose transporters in the Sprague Dawley rat. The reference strain was the Brown Norway rat [133].
List of Major Candidate Genes Involved in the Inflammation Pathway
| tumor necrosis factor receptor superfamily | chr3:156092602–156107426 | TNF-α, a potential mediator of insulin resistance, promotes serine phosphorylation of IRS-1 and -2, impairs the ability of IRS-1 and -2 to associate with the insulin receptor and inhibits insulin-stimulated tyrosine phosphorylation [54–56]. TNF-α is upregulated in Dahl S rats [52]. | ||
| Nuclear factor kappa-B-activating protein | chr X: 7,762,299–7,781,765. | Renal NF-{kappa}B is significantly upregulated in high-salt-fed Dahl S rats [58]. | ||
| Nuclear factor kappa-B kinase subunit beta | chr16: 73,805,082–73,858,088. | Inhibition of IKBKB with salicylates or through targeted gene disruption causes a dramatic improvement of insulin sensitivity in animal models of insulin resistance such as ob/ob mice and obese Zucker fatty rats [59,60]. | ||
| Interleukin-1β receptor accessory protein precursor | chr11: 76,092,840–76,222,495. | IL1β activates jnk which is upregulated in high-salt-fed Dahl S rats [57]. | ||
| interleukin 17D | chr 15: 36,566,307–36,583,168. | IL-17 D, a proinflammatory cytokine that enhances T cell priming and stimulates the production of proinflammatory molecules such as IL-1, IL-6, TNF-alpha, NOS-2, and chemokines resulting in inflammation. | ||
| Interleukin-10 precursor (IL-10) (Cytokine synthesis inhibitory factor) (CSIF). | chr 13: 43.95m | IL-10, also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. This cytokine can block NF-kappa B activity, and is involved in the regulation of the JAK-STAT signaling pathway. It is capable of inhibiting synthesis of pro-inflammatory cytokines like Interferon-gamma, IL-2, IL-3, TNFα and GM-CSF made by cells such as macrophages and the Type 1 T helper cells. | ||
| C-reactive protein precursor | chr 13: 88,674,743–88,715,585. | Insulin resistance and C-reactive protein (CRP) levels are strongly correlated in adults [110]. | ||
| Selenoprotein S (VCP-interacting membrane protein) (Sg2). | chr 1: 120,509,128–120,518,322. | In humans, polymorphisms in the encoded plama membrane selenoprotein (SEPS1, or SELS gene) correlate to diabetes mellitus and coronary heart diseases. The selenoprotein regulate red-ox balance and clear cells of misfolded proteins. Gene polymorphisms result in accumulation of these proteins even higher under cell stress. Carriers have higher IL1, -6, -10, and TNF [111]. | ||
| protein tyrosine phosphatase, non-receptor type 22 (lymphoid) (predicted) | chr 2: 199,083,234–199,132,761 | Tyrosine phosphatase gene (PTPN22) prevents spontaneous T-cell activation. In humans, mutations (C1858T, R620W) was associated with type 1 diabetes [112–114]. | ||
| Corticotropin-releasing factor receptor 1 precursor (CRF-R) (CRF1) (Corticotropin-releasing hormone receptor 1) (CRH-R 1). | chr 10: 93.31 m | Crhr1 is required for a normal chromaffin cell structure and function and deletion of this gene is associated with a significant impairment of epinephrine release. | ||
| Interleukin-6 precursor | chr 4: 456,799–461,376. | Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 [115]. | ||
| Interleukin-15 precursor. | chr 19: 27,482,376–27,499,255. | IL-15 increases insulin sensitivity therefore increasing glucose transport and utilization in muscles [116]. | ||
| interleukin 18 | chr 9: 39,676,026–39,698,748. | Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans [117,118]. | ||
| Dual specificity mitogen-activated protein kinase kinase 7 | chr 12: 1,543,467–1,552,353. | MAP2K7 selectively activates the JNKs which suppresses insulin signaling [57]. | ||
| Mitogen-activated protein kinase 6 or (Extracellular signal-regulated kinase 3) (ERK-3) (p55-MAPK). | chr 8: 80,212,726–80,236,362 | ERK3 associates with MAP2 and is involved in glucose-induced insulin secretion [119]. | ||
| Mitogen-activated protein kinase 4-isoform4 | chr 9: 39,070,845–39,211,446. | Map4k4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance [120]. | ||
| Dual specificity mitogen-activated protein kinase kinase 1 or (MAP kinase kinase 1) (MAPKK 1) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK1). | chr 8: 68,379,077–68,451,583. | MAP2K1 restored insulin action on glucose uptake by cells [120,121]. | ||
| C-Jun amino terminal kinase | chr 3: 76.78 m | JnK is activated by TNF-α and IL-β. Jnk forms a stable complex with IRS-1 and phosphorylates Ser307 that inhibits insulin stimulated tyrosine phosphorylation of IRS-1 [57]. | ||
| CX3C chemokine receptor 1 | chr 8: 125.03 m | Modulators of CX3CR1 can be used to treat diabetes, as well as diagnose diabetes by measuring the levels of CX3CR1 in a patient (US patents 2006). | ||
| C-C chemokine receptor type 3 | chr 8: 128.76 m | CCL3was reported to be increased in obese mice and to contribute to insulin resistance and macrophage recruitment [122]. | ||
| C-C chemokine receptor type 2 | chr 8: 128.89 m | CCR2 influences the development of obesity and associated adipose tissue inflammation and systemic insulin resistance [123]. | ||
| C-C chemokine receptor type 5 | chr 8: 128.91 m | CCR5 polymorphisms in children with insulin-dependent diabetes mellitus [124]. | ||
| NADPH oxidase 3 | chr 1: 38.64 m | NOX3, a ROS generating NADPH oxidase, plays an integral role in insulin-induced signal transmission [125]. | ||
| NADPH oxidase 4 | chr 1: 143.42 m | The NAD(P)H Oxidase Homolog Nox4 Modulates Insulin-Stimulated Generation of H2O2 and Plays an Integral Role in Insulin Signal Transduction [126]. | ||
| Prostaglandin G/H synthase 2 precursor (Cyclooxygenase-2) (COX-2) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II). | chr 13: 64,427,282–64,432,982. | PTGS2 generates prostaglandins, which negatively modulate glucose-stimulated insulin secretion, and functions as a mediator of the inflammatory response [127]. | ||
| Arachidonate 5-lipoxygenase (5-lipoxygenase) (5-LO) | chr 4: 152.61 m | The epidemiologic data suggest that subjects with two variant alleles will have greater ALOX5 gene expression, greater production of arachidonic acid-derived leukotrienes and a more "proinflammatory phenotype than subjects with two common alleles. | ||
| Arachidonate 5-lipoxygenase-activating protein (FLAP) (MK-886-binding protein). | chr 12: 6.25 m | ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance [128]. | ||
| Nitric-oxide synthase, endothelial (NOSIII) (Endothelial NOS) (eNOS) | chr 4: 6.16 m | The (-)786T-C mutation of the eNOS gene is associated with insulin resistance in both Japanese non-diabetic subjects and Type II diabetic patients [129] | ||
| Nitric oxide synthase, inducible (NOS type II) (Inducible NO synthase) (Inducible NOS) (iNOS) | chr 10: 65.04 m | obese | ||
| NADPH-cytochrome P450 reductase (CPR) (P450R). | chr 12: 22.08 m | NADPH-cytochrome P450 reductase (CPR) plays a role in type II diabetes [131] | ||
| Phospholipase A2 precursor | chr 12: 42.41 m | Mice with targeted inactivation of the group 1B phospholipase A [2] (Pla2glb) gene displayed lower postprandial glycemia than that observed in wild-type mice after being fed a glucose-rich meal [132]. |
Figure 6Steps Involved in Glucose Utilization. Schematic representation of the three steps involved in glucose utilization. In most cases, glucose transport is believed to be the rate limiting step. However, in conditions of hyperinsulinemia like that seen in high-salt-fed Dahl S rats, the rate limiting step may switch to phosphorylation [63,64]. Pertubations in any of these steps might precipitate the high salt-induced insulin resistance in Dahl S rats.
Figure 7Anticipated Results. Summary of Expected Results in the Proposed Studies: On high salt diet, IRS-1 and/or -2 mRNA and protein levels will be diminished in Dahl S versus R rats. No changes are anticipated in IRS-1 and/or -2 mRNA and protein levels in Dahl S rats on normal salt diet, or in Dahl R rats on any of the dietary treatments (low, normal and high salt diet). On low salt diet, IRS-1 and/or -2 mRNA and protein levels in Dahl S rats might not change or on the contrary they might increase because of the reduced levels of sodium acting on the salt-response element in the promoter region of IRS-1 and/or -2. It is postulated in the present hypothesis that this salt-responsive element possesses an inhibitory effect on IRS-1 and/or -2. The less salt the greater the IRS-1 and/or -2 mRNA and protein levels. Serine phosphorylation is expected to be enhanced in Dahl S versus R rats, possibly by the higher insulin levels in Dahl S rats.
Figure 8Anticipated Results. Summary of Expected Results in the Proposed Studies: Variants in the genes encoding the GLUT proteins in Dahl S rats, combined with high salt will decrease the activity of GLUT proteins and decrease glucose transport in Dahl S rats.